Guidelines for Complications of Cancer Treatment Vol VIII Part B

6. Bow EJ, Rotstein C, Noskin GA, et al. A randomizedopen-label multicenter comparative study of the efficacyand safety of piperacillin-tazobactum and cefepime forthe empirical treatment of febrile neutropenic episodesin patients with hematological malignanacies. Clin InfecDis.2006;43:447-4597. Granowetter L, Wells H, Lange BJ. Ceftazidime with orwithout vancomycin vs cephalothin, carbenicillin, andgentamicin as the initial therapy of the febrile neutropenicpediatric cancer patient. Pediatr Infect Dis J. 1988;7:165-1708. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH.Amphotericin B:time for a new gold standard. Clin InfectDis. 2003;37:415-4259. Winston DJ, Hathorn JW, Schuster MG et al. Amulticenter randomized trial of fluconazole versusamphotericin B for empiric antifungal therapy of febrileneutropenic patients with cancer. Am J Med.2000;108:282-28910. Boogaerts M, Winston DJ, Bow EJ et al. Intravenousand oral itraconazole versus intravenous amphotericinB deoxycholate as empirical antifungal therapy forpersistent fever in neutropenic fever patients with cancerwho are receiving broad-spectrum antibacterial therapy.A randomized control trial. An Intern Med. 2001; 135:412-42211. Walsh TJ, Pappas P, Winston DJ et al. Voriconazolecompared with liposomal amphotericin B empiricalantifungal therapy in patients with neutropenia andpersistent fever. N Eng J Med. 2002;346:225-23412. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofunginversus liposomal amphotericin B for empirical antifungaltherapy in patients with persistent fever and neutropenia.N Eng J Med. 2004;351:1391-1402392